{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:42:13Z","timestamp":1761982933778,"version":"build-2065373602"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Extended\u2010release injectable naltrexone (XR\u2010naltrexone) is an effective relapse prevention treatment of patients with opioid use disorder (OUD), but retention remains a problem. Previous trials have either only calculated the association of one or two predictors or used claims\u2010based datasets with only limited data to identify these characteristics. This analysis tested multiple baseline and clinical predictors for association with early retention on XR\u2010naltrexone using combined data from five consecutive studies enrolling patients with active opioid use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Bivariate associations between patients' demographic and clinical characteristics at baseline and during the weeks after the first XR\u2010naltrexone injection, and receipt of a second injection were calculated (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009200). Significant factors were included in a multivariable logistic regression model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>148\/200 participants (74%) received the second injection. Lower Hamilton\u2010Depression Scale (HAM\u2010D) scores after the first injection were significantly associated with receiving a second injection in univariate and multivariable analysis. The following factors were significantly associated with receipt of the second injection in the univariate but not in the multivariable model: longest period of abstinence 1\u201311 months, use of cocaine in the 7 days before enrollment, use of alcohol or cocaine in the week after first injection, lower severity of cravings for opioids after first injection, lower self\u2010report withdrawal scores after the first injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Scientific Significance<\/jats:title>\n                    <jats:p>Depressive symptoms after first XR\u2010naltrexone injection are associated with nonreceipt of a second injection. Clinicians should educate patients about this risk and monitor for possible depression symptoms after the first injection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajad.70055","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T09:44:01Z","timestamp":1749375841000},"page":"654-662","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trials"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-8895","authenticated-orcid":false,"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei\u2010Chen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Columbia University Vagelos College of Physicians and Surgeons New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Previously associated with Alkermes Inc. Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Greiner","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Ohrtman","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onumara","family":"Opara","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2055-3425","authenticated-orcid":false,"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-6462","authenticated-orcid":false,"given":"Adam","family":"Bisaga","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute and Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02190738"},{"issue":"2","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jurban\/jti049","article-title":"Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)","volume":"82","author":"Fischer B","year":"2005","journal-title":"J Urban Health: Bull New York Acad Med"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550881003684798"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"issue":"3","key":"e_1_2_8_6_1","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick RP","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_2_8_7_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12011"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100909"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.02.009"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.08.011"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.01.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.010"},{"key":"e_1_2_8_14_1","unstructured":"SAMHSA. Medications for Substance Use Disorders. April 11 2024. Accessed May 21 2025.https:\/\/www.samhsa.gov\/substance-use\/treatment\/options"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3206"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109343"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14180"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.12.004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.01.007"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.05.013"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490902927785"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.07.005"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1189659"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.20"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.08.019"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490500528464"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.01.005"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2019.1700265"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050548"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17070732"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080038006"},{"issue":"20","key":"e_1_2_8_35_1","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-70486-4_14"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(90)90036-W"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp425"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506879"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490290087929"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3537"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12527"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108667"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.70055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:39:15Z","timestamp":1761982755000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.70055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/ajad.70055"],"URL":"https:\/\/doi.org\/10.1111\/ajad.70055","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"type":"print","value":"1055-0496"},{"type":"electronic","value":"1521-0391"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"2024-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}